firstwordpharmaDecember 24, 2019
Tag: iBIO , EdgePoint AI , Gen Quality
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint's proprietary artificial intelligence ("AI")/blockchain-driven vision system for pharmaceutical manufacturing, known as TrustPoint Fabric. Initial implementation will occur at iBio's state-of-the-art production facility for the optimization of raw material documentation and verification activities.
Using blockchain technology, TrustPoint Fabric enables automated data generation and capture to remain immutable and fully auditable. Thus, when fully implemented, iBio aims to deliver the highest-level of compliance to the pharmaceutical industry's standards for data integrity. Concurrently, the enhanced automation capabilities are expected to lower operating costs while improving quality for clients of iBio's biologics contract development and manufacturing services.
"We are proud to take part in efforts to bring emerging technologies like TrustPoint Fabric into the pharmaceutical manufacturing realm," stated Robert Erwin, President of iBio. "Adding this technology to our automated biologics manufacturing facility is a natural fit and may yield substantial benefits. The potential to reduce costs by streamlining labor intensive manual operations while improving quality is very attractive as we continue to grow our position as the leading plant-based biologics CDMO."
"We are excited that a leading plant-based CDMO like iBio has chosen to pilot TrustPoint Fabric," commented Vuong Trieu, Ph.D., CEO of Mateon Therapeutics. "The platform has broad application potential across virtually all types of pharmaceutical manufacturing including biologics, cell and gene therapy, small molecule manufacturing, bulk drug substance, fill finish, packaging and labeling. Accordingly, and assuming everything goes as planned, we envision the application of TrustPoint Fabric in iBio's cGMP manufacturing raw material supply chain will be the first in a series of implementations, both with iBio as well as other potential EdgePoint customers."
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: